J N Ingle
Overview
Explore the profile of J N Ingle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
2489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luen S, Viale G, Nik-Zainal S, Savas P, Kammler R, DellOrto P, et al.
Ann Oncol
. 2023 Jan;
34(4):397-409.
PMID: 36709040
Background: Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that...
2.
Coates A, Goldhirsch A, Gelber R, Ingle J, Thuerlimann B, Senn H
Ann Oncol
. 2020 Jun;
20(10):1751-1752.
PMID: 32560022
No abstract available.
3.
Yerushalmi R, Dong B, Chapman J, Goss P, Pollak M, Burnell M, et al.
Ann Oncol
. 2017 Apr;
28(7):1560-1568.
PMID: 28379421
Background: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. Methods: Data from chemotherapy trials MA.5 and MA.21; endocrine...
4.
Iankov I, Kurokawa C, DAssoro A, Ingle J, Domingo-Musibay E, Allen C, et al.
Cancer Gene Ther
. 2015 Aug;
22(9):438-44.
PMID: 26272026
Oncolytic measles virus (MV) strains have demonstrated broad spectrum preclinical anti-tumor efficacy, including breast cancer. Aurora A kinase controls mitotic spindle formation and has a critical role in malignant transformation....
5.
6.
Province M, Goetz M, Brauch H, Flockhart D, Hebert J, Whaley R, et al.
Clin Pharmacol Ther
. 2013 Sep;
95(2):216-27.
PMID: 24060820
The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from...
7.
Asiedu M, Beauchamp-Perez F, Ingle J, Behrens M, Radisky D, Knutson K
Oncogene
. 2013 Mar;
33(10):1316-24.
PMID: 23474758
Despite significant progress in the treatment of breast cancer, particularly through the use of targeted therapy, relapse and chemoresistance remain a major hindrance to the fight to minimize the burden...
8.
Goss P, Ingle J, Martino S, Robert N, Muss H, Livingston R, et al.
Ann Oncol
. 2012 Oct;
24(2):355-361.
PMID: 23028039
Background: MA17 showed improved outcomes in postmenopausal women given extended letrozole (LET) after completing 5 years of adjuvant tamoxifen. Patients And Methods: Exploratory subgroup analyses of disease-free survival (DFS), distant...
9.
Cigler T, Richardson H, Yaffe M, Fabian C, Johnston D, Ingle J, et al.
Breast Cancer Res Treat
. 2011 Jan;
126(2):453-61.
PMID: 21221773
We hypothesized that exemestane (EXE) would reduce mammographic breast density and have unique effects on biomarkers of bone and lipid metabolism. Healthy postmenopausal women were randomized to EXE (25 mg...
10.
Goldhirsch A, Ingle J, Gelber R, Coates A, Thurlimann B, Senn H
Ann Oncol
. 2009 Jun;
20(8):1319-29.
PMID: 19535820
The 11(th) St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups...